Exparel相关论文
2011年11月,美国FDA批准了Pacira制药有限公司开发的布比卡因(bupivacaine)1.3%脂质体注射用悬浮液Exparel,用于直接注射至手术部......
美国Pacira公司的布比卡因多囊脂质体Exparel于2011年获FDA批准上市至今已近十年,临床优势明显且取得了巨大市场成功,其与Depofoam......
Use of Liposomal Bupivacaine (Exparel) for Reduction in the Use of Postoperative Narcotics in an Obe
Background: Obesity, particularly in the setting of comorbid disease, presents a unique challenge. Clinicians are pursui......
Evaluation of the Efficacy of Liposomal Bupivacaine Infiltrated into the Posterior Capsule for Posto
Achieving adequate control of postsurgical pain remains a challenge in patients undergoing Total Knee Arthroplasty (TKA)......
A Case Series of 12 Patients Receiving Bilateral Transverse Abdominis Plane Blocks after Cesarean Se
Transverse abdominis Plane blocks (TAP) provide effective postoperative analgesia following surgical incisions of the lo......
Post-operative analgesia is both necessary for patient comfort and satisfaction. Peripheral nerve block offer both good ......
长效酰胺类局麻药布比卡因常常用于术后镇痛,普通注射剂(浓度0.5%)产生不足7 h的镇痛作用,2011年美国食品药品监督管理局批准布比......
